DES MOINES, Iowa, Oct. 2, 2024 /PRNewswire/ -- Ambetter Health, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will now offer Iowans a variety of affordable health insurance plans to residents in 33 counties in Iowa in 2025. Open enrollment for the Health Insurance Marketplace for Iowa runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15 for coverage starting Jan. 1, 2025.
"With Ambetter Health, we've designed a variety of coverage options to help individuals access viable health solutions designed to meet their unique needs," said Mitch Wasden, Plan President & CEO of Iowa Total Care. "Our commitment is not just to provide high-quality insurance, but to build a healthier Iowa for all, where every member feels valued, supported and equipped to thrive."
Ambetter Health offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Below is a full list of the counties in which Ambetter Health will be offered in 2025:
Iowa residents interested in learning more about Ambetter Health or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ia.
About Ambetter Health
Ambetter Health serves under-insured and uninsured populations through the federal Health Insurance Marketplace. Ambetter Health is underwritten by Iowa Total Care, Inc., which is a Qualified Health Plan issuer in Iowa. For more information, please visit ambetterhealth.com/en/ia/. This is a solicitation for insurance. For information on your right to receive an Ambetter Health plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$63.52 |
Daily Change: | 1.74 2.82 |
Daily Volume: | 5,286,820 |
Market Cap: | US$33.410B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB